These findings demonstrate that patients with relapsed multiple myeloma treated with Kyprolis lived twice as long without disease worsening as those treated with bortezomib
The safety and efficacy of Farydak in combination with bortezomib
and dexamethasone was demonstrated in 193 clinical trial participants with multiple myeloma who received at least two prior treatments that included bortezomib
and an immunomodulatory agent.
Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II Abstract #: 2765 Title: The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY-1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib
Authors Affiliated with the Following Institutions: Virginia Commonwealth University and University of Rochester Description: These findings indicate that combining the selective HDAC6 inhibitor ACY-1215 with carfilzomib (CFZ) synergistically in preclinical models induces apoptosis in low- and high-risk diffuse large B-cell lymphoma (DLBCL) and in mantle cell lymphoma (MCL) cells through a JNK-dependent process in association with G2M arrest, down-regulation of HR23B, and induction of DNA damage.
Patients will also receive bortezomib
and dexamethasone on days 1, 8 and 15.
Jane Griffiths, Company Group Chairman, Janssen Europe, Middle-East, Africa, commented: "This positive opinion is a decisive step in making subcutaneous bortezomib
available to all patients who suffer from multiple myeloma.
375 mg/Kg IV), one of two different dose levels of bortezomib
In ENDEAVOR, the rates for cardiac and renal failure were higher in the Kyprolis arm versus the bortezomib
c]ABenefit of bortezomib
, in combination with melphalan and prednisone (VMP), seen across multiple patient subgroups regardless of subsequent extensive therapy
8 months in patients who received >2 prior lines of therapy, including bortezomib
Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib
and Other Treatments: An Analysis of the US Seer-Medicare Linked Database
90 percent of patients had prior bortezomib
exposure and 26 percent were bortezomib
refractory, 88 percent had previous lenalidomide exposure, 62 percent had prior thalidomide exposure and 12 percent had prior carfilzomib/marizomib exposure.
Combination study of venetoclax with bortezomib
and dexamethasone showed 83 percent overall response rate in bortezomib
-naive patients and a 63 percent overall response rate in bortezomib
Drug: Liposomal Doxorubicin, Bortezomib
, etravirine, Rilpivirine, Darunavir, Telaprevir
A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib
In Patients with Relapsed Multiple Myeloma.
al, pre-published online April 4, 2012, Zalicus researchers, in collaboration with the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, have discovered that adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib